Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 7 includes Village Super Market, MARA Holdings, ...

Citi analyst David Lebowitz has maintained their bullish stance on MDGL stock, giving a Buy rating yesterday.Invest with Confidence: Follow ...

Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research ...

2025年1月27日， Madrigal（MDGL）披露4笔公司内部人交易情况。董事Sibold William John于2025年1月24日卖出1584股。

Chief Commercial Officer of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a $6.79 billion market cap biopharmaceutical company whose stock has gained nearly 12% in the past week, recently sold 347 ...

The transaction was executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Madrigal Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor ...

Here's the list of options activity happening in today's session: These bullet-by-bullet explanations have been constructed ...

根据提交给美国证券交易委员会的Form 4文件显示，Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL)的总法律顾问Kelley Shannon ...